In consultation: Guidance and quality standards
Showing 1 to 7 of 7
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Secukinumab for treating relapsed polymyalgia rheumatica ID6599 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Draft guidance | Technology appraisal guidance | |
| Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Topical tapinarof for treating mild to severe plaque psoriasis ID6712 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] | Draft guidance | Technology appraisal guidance | |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |